

# Replacement of the *p16/CDKN2* Gene Suppresses Human Glioma Cell Growth<sup>1</sup>

Wadih Arap, Ryo Nishikawa, Frank B. Furnari, Webster K. Cavenee, and H-J. Su Huang<sup>2</sup>

Ludwig Institute for Cancer Research [W. A., R. N., F. B. F., W. K. C., H-J. S. H.], Department of Medicine [W. K. C., H-J. S. H.], and Center for Molecular Genetics [W. K. C.], University of California, San Diego, La Jolla, California 92093-0660, and Cancer Biology Program, Stanford University, Stanford, California 94305 [W. A.]

## ABSTRACT

The *p16/CDKN2* gene has many features of a growth suppressor gene: it maps to 9p21, a frequent region of loss of heterozygosity in a variety of tumor types; it encodes an inhibitor of cyclin-dependent kinase 4; and its homozygous deletion is common in tumor-derived cell lines. However, the lower frequency of alteration of the gene in primary tumor tissue as compared to the cognate tumor cell lines has brought this interpretation into question. We have assessed the growth suppressive function of *p16/CDKN2* by gene transfer. The introduction of full-length *p16/CDKN2* cDNA caused marked growth suppression in *p16/CDKN2*-null human glioma cells, but was without significant effect in those cells with endogenous wild-type *p16/CDKN2* alleles. These results provide functional evidence in support of the hypothesis that the *p16/CDKN2* gene is a functional growth suppressor gene, at least in gliomas.

## INTRODUCTION

The clonal evolution of human tumors appears to derive from an accumulation of genetic alterations that are advantageous to growth (1). This hypothesis has been tested most rigorously in human colon cancer (2) and gliomas (3). In the latter tumor type, a series of events occurring in a relatively defined order have been identified and include loss of heterozygosity for chromosome 17p, mutation of the *p53* gene, deletion of chromosome 9p, amplification and alteration of the epidermal growth factor receptor gene, and monosomy of chromosome 10 (3). Among these lesions, deletions involving chromosome region 9p21 appear to be the most common structural abnormality observed in grade III and grade IV malignant gliomas, where they are detected in up to one half of primary tumor samples (3, 4) and up to two thirds of glioma cell lines (4, 5). Recently, a candidate tumor suppressor gene, *p16/CDKN2*, located between the *IFN-α* and *methylthioadenosine phosphorylase* loci in the 9p21 region has been reported (6-8).

*p16<sup>INK4</sup>* belongs to a newly described class of cyclin-dependent kinase inhibitory proteins that also includes *p15<sup>INK4B</sup>*, *p21<sup>WAF1</sup>*, and *p27<sup>KIP1</sup>* (6) and which may provide a connection between tumor suppression and cell cycle regulation. Four distinct lines of evidence promote the candidacy of the *p16/CDKN2* gene as a growth suppressor: (a) It maps to 9p21, a chromosome region frequently deleted in many tumor types including glioma, malignant melanoma, leukemia, osteosarcoma, and carcinomas of lung, kidney, ovary, pancreas, breast, bladder, head and neck, and esophagus (7-12). (b) Homozygous deletions and intragenic mutations of the *p16/CDKN2* gene itself are frequent in cell lines derived from these human tumors (7-14). (c) Mutations in the *p16/CDKN2* gene appear to underlie some cases of familial malignant melanoma (10, 14, 15). (d) The *p16/CDKN2* product specifically inhibits cyclin-dependent kinase 4-cyclin D activity *in vitro* (16), suggesting that the *p16<sup>INK4</sup>* protein may be a negative regulator of proliferation (6, 16).

On the other hand, two observations have challenged this interpretation: (a) Although *p16/CDKN2* gene alterations are common in cultured cell lines, the frequency of homozygous deletions and mutations in primary uncultured tumors is much lower (12-14, 17, 18). (b) Transfer of *p16/CDKN2* cDNA of the originally published sequence into human esophagus, lung, liver, ovary, and mesothelioma tumor cell lines had only a modest and variable growth inhibitory effect (19).

To specifically address the hypothesis that the *p16/CDKN2* gene is a growth suppressor in human glioma cells, we have transfected full-length *p16/CDKN2* cDNA into cultured glioma cells having either deleted or wild-type endogenous *p16/CDKN2* alleles. The introduction of the *p16/CDKN2* gene led to a pronounced growth suppression in cells lacking the endogenous gene but had minimal effects on cells with wild-type alleles in support of the contention that the *p16/CDKN2* gene can function as a growth suppressor in human glioma.

## MATERIALS AND METHODS

**Cell Lines.** The glioma cell lines used in this study were described previously (20, 21) and were derived from glioblastomas except LN-319 and U-373MG, which originated from astrocytomas, and D-247MG, which was derived from a gliosarcoma. CCD-43SK, a normal skin fibroblast cell line used, was obtained from the American Type Culture Collection (Bethesda, MD).

**Reverse Transcriptase-PCR, Cloning, and Sequencing of *p16/CDKN2*.** First-strand *p16/CDKN2* cDNA synthesis was accomplished using a Stratascript RT-PCR kit (Stratagene, La Jolla, CA). Amplification of *p16/CDKN2* full-length cDNA was performed as a two-step procedure. Two overlapping fragments were amplified using primers 5'-CGGAGAGGGG-GAGAACAGACAACG-3' (sense) and 5'-CCAGGAAGCCCTCCCGG-3' (antisense) for the 5' fragment, and primers 5'-CCGCACTTACCCG-3' (sense) and 5'-ACCTTCGGTGACTGATGATCTAAG-3' (antisense) for the 3' fragment of the gene. Then, the isolated 5' and 3' fragments were mixed in equimolar amounts and a recombinant PCR reaction (22) was performed using primers 5'-CGGAGAGGGG-GAGAACAGACAACG-3' and 5'-ACCTTCGGTGACTGATGATCTAAG-3' modified to contain *Bam*HI and *Xho*I sites, respectively. PCR conditions were 65°C for annealing and 72°C for extension, in the presence of 2% DMSO (American Type Culture Collection), for 35 cycles. *p16/CDKN2* cDNA was subcloned into *Bam*HI/*Xho*I sites of the mammalian expression vector pcDNA3 (Invitrogen, San Diego, CA), and at least 10 individual clones per cell line were isolated, pooled, and sequenced using a Sequenase kit (USB, Cleveland, OH). A clone containing the wild-type *p16/CDKN2* cDNA, derived from CCD-43SK fibroblasts, was designated as *pCDKN2WT*. This clone contained eight additional amino acids at its NH<sub>2</sub> terminus as compared to the originally reported sequence (16) but identical to recent revisions (19, 23). Moreover, codon 35 was GGG (glycine), consistent with many other reported sequences (11, 19, 24), but different from the original published clone (16) in which codon 35 was GTG (valine).

**Nucleic Acid Isolation and Blot Analysis.** Genomic DNA was extracted using standard procedures (25). Ten μg genomic DNA from each cell line were digested with *Eco*RI, separated by electrophoresis, blotted onto nylon membranes, and hybridized with a <sup>32</sup>P-labeled *p16/CDKN2* cDNA probe covering nucleotides 25-960 (16). Genomic DNA integrity was determined by rehybridizing the Southern blots with the *ABL* gene, located on the chromosome 9q arm.

RNA was isolated using Trizol reagent (GIBCO-BRL, Gaithersburg, MD). A 5' region *p16/CDKN2*-specific <sup>32</sup>P-labeled probe containing 172 base pairs (nucleotides -40 to 132) was generated by PCR using primers 5'-CG-

Received 11/21/94; accepted 1/18/95.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

<sup>1</sup> This work was supported in part by the CNPq/Brazilian National Research Council (W. A.) and by the Robert Steel Foundation for Pediatric Cancer Research (F. B. F.).

<sup>2</sup> To whom requests for reprints should be addressed, at Ludwig Institute for Cancer Research, 9500 Gilman Drive, La Jolla, CA 92093-0660.

GAGAGGGGAGAACAGACAACG-3' (sense) and 5'-GCCTCCGACCG-TAACTATTCGG-3' (antisense). Twenty  $\mu\text{g}$  total cellular RNA were electrophoresed through a 1% denaturing agarose gel and blotted onto nylon membranes. Northern blot hybridization and washes were performed using Quickhyb solution (Stratagene, La Jolla, CA). RNA quality and blotting efficiency were confirmed by reversible methylene blue staining of the blot (26).

**Western Blot Analysis.** Cells ( $4 \times 10^4$  cells/well) in a 12-well plate were cultured overnight in medium containing 10% fetal bovine serum, washed with 1X PBS, lysed with 200  $\mu\text{l}$  lysis buffer (0.064 M Tris-HCl pH 6.8, 1.28% SDS, 12.8% glycerol, 1.28% 2-mercaptoethanol, 0.25% bromophenol blue), and then boiled. Cell lysates were size fractionated through SDS-PAGE and transferred onto nitrocellulose membranes as described (27). Membranes were probed with anti-p16/CDKN2 rabbit polyclonal antibody (PharMingen, San Diego, CA) and proteins were detected by chemiluminescence (Amersham Corp., Arlington Heights, IL).

**Transfection Assays.** Transfections were performed using the calcium phosphate method (28) in duplicate dishes and in at least four independent experiments. Briefly, 20  $\mu\text{g}$  of either pCDKN2WT or pCDNA3 were used per 10-cm dish. Transfections were terminated after 12 h. Forty-eight-h posttransfection, cells were split at a 1:5 dilution and maintained for 7 days in G418-containing (Geneticin; GIBCO-BRL) media. Trypan blue excluding cells were counted using a hemocytometer.

**RESULTS**

**Selection of Recipients.** In order to identify appropriate recipients for p16/CDKN2 gene transfer, we analyzed the endogenous genes of a panel of 16 glioma lines; the data are summarized in Table 1. Southern blot analysis showed that 4 (25%) of 16 cell lines (LN-215, LN-235, LN-319, and LN-Z308) carried detectable p16/CDKN2 genes, while the other 12 (75%) of 16 cases had homozygously deleted p16/CDKN2 genes. To rule out intragenic alterations (such as small deletions/insertions or point mutations) that would be undetectable by Southern blot analysis, we sequenced the cDNAs derived from the four p16/CDKN2-positive glioma cell lines, and found that they were all identical to the wild-type sequence obtained for pCDKN2WT (see "Materials and Methods").

Western blot analysis of the p16/CDKN2 product was consistent with the Southern blot and sequencing results, with p16<sup>INK4</sup> protein being detected in the glioma lines LN-215, LN-235, LN-319, and LN-Z308. These observations are in concordance with other reports showing frequent (71–87%) p16/CDKN2 homozygous deletions in glioma-derived cell lines (7, 9).

For transfection studies, we selected five glioma lines. Three (T98G, U-87MG, and U-251MG) had endogenously deleted p16/CDKN2 genes, while two (LN-319 and LN-Z308) contained wild-type




Fig. 1. Analysis of p16/CDKN2 in human glioma cell lines. A, Southern blot analysis. DNA fragments were hybridized with a p16/CDKN2 probe (see "Materials and Methods"). The 4.3-kilobase band represents the p16/CDKN2 gene, right. The 6.0-kilobase band may represent cross-hybridization with the p15<sup>INK4B</sup> (MTS2) gene. B, Northern blot analysis. Two p16/CDKN2 RNA transcripts of 0.8 and 1.1 kilobases, which hybridize with a p16/CDKN2-specific probe, right. C, methylene blue staining (26) of the nylon membrane blot in B to demonstrate transfer efficiency. Only 18S rRNA is shown. D, Western blot analysis. Size markers, right. ◀, p16<sup>INK4</sup> product; ●, nonspecific protein cross-reaction with the anti-p16<sup>INK4</sup> polyclonal antibody serves as an internal control.

Table 1 p16/CDKN2 gene and p16<sup>INK4</sup> protein in a panel of human glioma cell lines

Cell line	Southern blot	Western blot	cDNA
LN-215	+	+	Wild-type
LN-235	+	+	Wild-type
LN-319	+	+	Wild-type
LN-Z308	+	+	Wild-type
A-172	-	-	N/A
D-247MG	-	-	N/A
LN-18	-	-	N/A
LN-229	-	-	N/A
LN-340	-	-	N/A
LN-382T	-	-	N/A
LN-428	-	-	N/A
LN-443	-	-	N/A
T98G	-	-	N/A
U-87MG	-	-	N/A
U-251MG	-	-	N/A
U-373MG	-	-	N/A

<sup>a</sup> +, present; -, altered or missing; N/A, not applicable.

p16/CDKN2 alleles. Southern blot analysis (Fig. 1A) showed a 4.3-kilobase band that represents the p16/CDKN2 gene. A larger band of 6.0 kilobases was noted in the positive cell lines as well as in the T98G line and may represent cross-hybridization to the recently cloned p15<sup>INK4B</sup> gene (23). Southern blots reprobbed with pabIK2, an ABL gene probe located on chromosome arm 9q, revealed bands of similar intensity in all five cell lines, confirming the integrity of the genomic DNA (data not shown). Two transcripts of 1.1 and 0.8 kilobases were apparent on the Northern blot of LN-319 and in LN-Z308, while no message could be detected in the p16/CDKN2 gene null lines (Fig. 1B) although nucleic acid loading was equivalent (Fig. 1C). A 16–17-kDa protein was detected in LN-319 and LN-Z308, but not in the other three lines by Western blotting (Fig. 1D).

**p16/CDKN2 Gene Transfer.** To test the growth suppressive abilities of p16/CDKN2, we introduced a full-length cDNA into T98G,




Fig. 2. Effects of *p16/CDKN2* gene introduction in human glioma cell growth. pCDKN2WT (▨) or vector alone (■) were transfected by the calcium phosphate method in duplicate 100-mm dishes. Viable cell counts were determined after G-418 selection. A typical experiment is shown. Results were reproduced in at least four independent experiments. The results are normalized in terms of percentage of vector transfection, setting the vector control to 100% in each case.

U-87MG, U-251MG, LN-319, and LN-Z308 cells and compared the resultant growth response to that when the cells were transfected with empty vector sequence. The results in Fig. 2 show that the cell number was reduced in the presence of the *p16/CDKN2* gene to (mean ± SE) 11.0% ± 0.4% of vector control for T98G, 19.6% ± 1.4% for U-87MG, and 5.2% ± 1.0% for U-251MG. On the other hand, for the wild-type *p16/CDKN2* glioma lines, the observed percentages of vector transfection were 109.0% ± 8.6% for LN-319 and 82.4% ± 10.0% for LN-Z308. Therefore, in each of the *p16/CDKN2*-negative cell lines, replacement of this gene resulted in marked growth suppression, while in the *p16/CDKN2* wild-type cell lines there was no significant growth inhibition by the introduction of the exogenous *p16/CDKN2* gene. Moreover, since these results were obtained with the bulk population of transfected cells, the possibility of clonal variation is minimized.

To confirm that the growth inhibitory effect was the consequence of the expression of the introduced *p16/CDKN2* gene, we analyzed transfectants of a null background glioma line (U-251MG) and a wild-type background glioma line (LN-319). Cells were harvested and these studies were performed 7–10 days posttransfection. Fig. 3A demonstrates expression of the transfected *p16/CDKN2* gene as the 0.95-kilobase transcript of the exogenous *p16/CDKN2* gene seen in U-251MG, which can be readily distinguished from the 0.8- and 1.1-kilobase endogenous transcripts present in LN-319. The level of RNA expression obtained from pCDKN2WT was roughly comparable to the level of endogenous RNA expression in the wild-type cells. Moreover, p16<sup>INK4</sup> protein expression was demonstrated by Western blot analysis of the transfected cells after selection. As expected, no p16<sup>INK4</sup> protein was detected in vector-transfected U-251MG cells. However, the levels of the p16<sup>INK4</sup> protein were indistinguishable among pCDKN2WT-transfected U-251MG, vector-transfected LN-319, or pCDKN2WT-transfected LN-319. The other glioma lines used for transfections revealed similar Northern and Western blot results (data not shown).

These data indicate that the growth suppression of *p16/CDKN2*-negative glioma cells transfected with pCDKN2WT was achieved at levels of protein expression very similar to that of the *p16/CDKN2* present endogenously in wild-type glioma cells. Since the introduction of additional copies of *p16/CDKN2* into a wild-type background had negligible effects in p16<sup>INK4</sup> protein expression (despite a moderate increase in *p16/CDKN2* RNA expression), it is possible that the

endogenous *p16/CDKN2* gene may be subject to homeostatic auto-regulation.

## DISCUSSION

Genomic deletion mapping studies implicate a gene on chromosome 9p in the progression of astrocytic tumors (3). Thus far, it has been unclear whether the *p16/CDKN2* gene is the target of the 9p21 deletions seen in gliomas, or whether the actual target is another recessive tumor suppressor gene located nearby (17, 29). Here, we have shown that the expression of p16<sup>INK4</sup> (at levels comparable to those in glioma cells expressing endogenous *p16/CDKN2*) specifically suppresses the growth of *p16/CDKN2*-negative glioma cells. In contrast, *p16/CDKN2* wild-type glioma cell growth was not affected by introduction of additional copies of *p16/CDKN2*. These results support the hypothesis that the *p16/CDKN2* gene is a functional suppressor of growth in glioma cells.




Fig. 3. Expression of endogenous and transfected *p16/CDKN2* gene in glioma cells. A, Northern blot analysis. The 0.8- and 1.1-kilobase *p16/CDKN2* endogenous transcripts, right. ●, 0.95-kilobase size transcripts of the exogenous *p16/CDKN2* gene introduced by transfection. B, methylene blue staining (26) of the nylon membrane blot in A to demonstrate transfer efficiency. Only 18S rRNA is shown. C, Western blot analysis. p16<sup>INK4</sup> product, right. The other human glioma cell lines used in this study revealed similar Northern and Western blot patterns of *p16/CDKN2* expression (data not shown).

Other investigators suggested that transfection of the *p16/CDKN2* gene inhibits growth and is selected against in the transfected cells, explaining the absence of detection of p16<sup>INK4</sup> in their expanded populations (19). Since we could clearly detect p16<sup>INK4</sup> protein expression by Western blot in our selected transfectants, this discrepancy could be attributed either to the transfection of an incomplete *p16/CDKN2* cDNA (19, 23) or, perhaps, to cell-specific differences.

Four of the cell lines we analyzed expressed the wild-type *p16/CDKN2* gene. The mechanism or mechanisms by which these cells override p16<sup>INK4</sup> growth suppression remains unclear. One possibility is amplification or overexpression of targets such as cyclin-dependent kinase 4 (30, 31) or cyclin D. An alternate to this may be the inactivation of another growth inhibitory pathway, such as that involving p53-p21<sup>WAF1</sup>. Since p16<sup>INK4</sup> is an inhibitor of the CDK4-cyclin D complex, while p53 is an activator of transcription of another cyclin-dependent kinase-inhibitory protein (p21<sup>WAF1</sup>) (6), the expression of either wild-type *p16/CDKN2* or wild-type *p53* would predictably be growth suppressive and cells with inactivation of either one or both of these genes could be expected to have a survival advantage. We have characterized the *p53* gene in two of the four wild-type *p16/CDKN2* glioma cell lines studied and found it mutated (LN-319) or rearranged (LN-Z308), consistent with this notion (21). Additionally, among the eight *p16/CDKN2*-negative glioma cell lines for which the *p53* gene has been characterized (21), six had inactivation of at least one allele of *p53* (LN-18, LN-229, LN-428, U-251MG, U-373MG, and T98G) and two had wild-type *p53* alleles (D-247MG and U-87MG). Thus, we could not identify a glioma line simultaneously containing intact *p53* and *p16/CDKN2* genes, supporting the hypothesis that the inactivation of at least one of these two genes is necessary for cell growth. Conversely, the inactivation of one of these two genes may not be sufficient to allow glioma cell growth. For example, a comparison of the growth of LN-319 and LN-Z308 to the growth inhibition effected in the *p16/CDKN2*-replaced T98G and U-251MG lines shows that although the genetic backgrounds in terms of these two genes in both groups appear to be similar (intact *p16/CDKN2* and mutated *p53*), their growth responses likely depend on additional factors. Nevertheless, the present results indicate that *p16/CDKN2* growth inhibition is independent of the *p53* status of the glioma cell lines used. Others have also suggested that the *p16/CDKN2* gene is often mutated or deleted in cell lines containing wild-type *p53*, and is often found intact in cell lines containing mutated *p53* genes (13, 14).

## ACKNOWLEDGMENTS

We thank Drs. Erwin G. Van Meir and Nicolas de Tribolet for the LN series of glioma cell lines; Darrel Bigner for the D-247MG glioma cell line; David H. Beach for the clone Bluescript SK/p16; Manuel Serrano, Douglas J. Demetrick, Tsutomu Nobori, and Dennis A. Carson for helpful discussions, and Aikou Okamoto and Curtis C. Harris for communication of results prior to publication (Ref. 19).

## REFERENCES

- Nowell, P. C. The clonal evolution of tumor cell populations. *Science* (Washington DC), 194: 23-28, 1976.
- Fearon, E. R., and Vogelstein, B. A genetic model for colorectal carcinogenesis. *Cell*, 61: 759-767, 1990.
- Louis, D. N., Seizinger, B. R., and Cavenee, W. K. Molecular genetic basis of cerebral gliomas. In: M. L. J. Apuzzo (ed.), *Benign Cerebral Gliomas*, pp. 163-180. Lebanon, NH: AANS Publication, 1995.
- Olopade, O. I., Jenkins, R. B., Ransom, D. T., Malik, K., Pomykala, H., Nobori, T., Cowan, J. M., Rowley, J. D., and Diaz, M. O. Molecular analysis of deletions of the short arm of chromosome 9 in human gliomas. *Cancer Res.*, 52: 2523-2529, 1992.
- James, C. D., He, J., Collins, V. P., Allalunis, T. M., and Day, R. S., III. Localization of chromosome 9p homozygous deletions in glioma cell lines with markers constituting a continuous linkage group. *Cancer Res.*, 53: 3674-3676, 1993.
- Serrano, M., Hannon, G. J., and Beach, D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. *Nature* (Lond.), 366: 704-707, 1993.
- Kamb, A., Gruis, N. A., Weaver, F. J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., III, Johnson, B. E., and Skolnick, M. H. A cell cycle regulator involved in genesis of many tumor types. *Science* (Washington DC), 264: 436-440, 1994.
- Nobori, T., Miura, K., Wu, D. J., Lois, A., Takabayashi, K., and Carson, D. A. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. *Nature* (Lond.), 368: 753-756, 1994.
- Peter, M., and Herskowitz, I. Joining the complex: cyclin-dependent kinase inhibitory proteins and the cell cycle. *Cell*, 79: 181-184, 1994.
- Mori, T., Miura, K., Aoki, T., Nishihira, T., Mori, S., and Nakamura, Y. Frequent somatic mutation of the *MTS1/CDK4I* (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. *Cancer Res.*, 54: 3396-3397, 1994.
- Kamb, A., Shattuck-Eidens, D., Eeles, R., Liu, Q., Gruis, N. A., Ding, W., Hussey, C., Tran, T., Miki, Y., Weaver-Feldhaus, J., McClure, M., Aitken, J. F., Anderson, D. E., Bergman, W., Frants, R., Goldgar, D. E., Green, A., MacLennan, R., Martin, N. G., Meyer, L. J., Youl, P., Zou, J. J., Skolnick, M. H., and Cannon-Albright, L. A. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. *Nature Genet.*, 8: 22-26, 1994.
- Caldas, C., Hahn, S. A., da Costa, L. T., Redston, M. S., Schutte, M., Seymour, A. B., Weinstein, C. L., Hruban, R. H., Yeo, C. J., and Kern, S. E. Frequent somatic mutations and homozygous deletions of the p16 (*MTS1*) gene in pancreatic adenocarcinoma. *Nature Genet.*, 8: 27-32, 1994.
- Spruck, C. 3., Gonzalez, Z. M., Shibata, A., Simoneau, A. R., Lin, M. F., Gonzales, F., Tsai, Y. C., and Jones, P. A. p16 gene in uncultured tumours. *Nature* (Lond.), 370: 183-184, 1994.
- Zhang, S. Y., Klein-Szanto, A. J. P., Sauter, E. R., Shafarenko, M., Mitsunaga, S., Nobori, T., Carson, D. A., Ridge, J. A., and Goodrow, T. L. Higher frequency of alterations in the *p16/CDKN2* gene in squamous cell carcinoma cell lines than in primary tumors of the head and neck. *Cancer Res.*, 54: 5050-5053, 1994.
- Ohta, M., Nagai, H., Shimizu, M., Rasio, D., Berd, D., Mastrangelo, M., Singh, A. D., Shields, J. A., Shields, C. L., Croce, C. M., and Huebner, K. Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, *CDK4I*, in melanoma. *Cancer Res.*, 54: 5269-5272, 1994.
- Hussussian, C. J., Struwing, J. P., Goldstein, A. M., Higgins, P. A. T., Ally, D. S., Sheahan, M. D., Clark Jr., W. H., Tucker, M. A., and Dracopoli, N. C. Germline p16 mutations in familial melanoma. *Nature Genet.*, 8: 15-21, 1994.
- Cairns, P., Mao, L., Merlo, A., Lee, D. J., Schwab, D., Eby, Y., Tokino, K., van der Riet, P., Blaugrund, J. E., and Sidransky, D. Rates of p16 (*MTS1*) mutations in primary tumors with 9p loss. *Science* (Washington DC), 265: 415-416, 1994.
- Xu, L., Sgroi, D., Sterner, C. J., Beauchamp, R. L., Pinney, D. M., Keel, S., Ueki, K., Rutter, J. L., Buckler, A. J., Louis, D. N., Gusella, J. F., and Ramesh, V. Mutational analysis of *CDKN2* (*MTS1/p16<sup>INK4</sup>*) in human breast carcinomas. *Cancer Res.*, 54: 5262-5264, 1994.
- Okamoto, A., Demetrick, D. J., Spillare, E. A., Hagiwara, K., Hussain, S. P., Bennett, W. P., Forrester, K., Gerwin, B., Serrano, M., Beach, D. H., and Harris, C. C. Mutations and altered expression of p16<sup>INK4</sup> in human cancer. *Proc. Natl. Acad. Sci. USA*, 91: 11045-11049, 1994.
- Van Meir, E. G., Ceska, M., Effenberger, F., Waltz, A., Grouzmann, E., Desbaillets, I., Frei, K., Fontana, A., and de Tribolet, N. Interleukin-8 is produced in neoplastic and infectious diseases of the human central nervous system. *Cancer Res.*, 52: 4297-4305, 1992.
- Van Meir, E. G., Kikuchi, T., Tada, M., Li, H., Diserens, A.-C., Wojcik, B. E., Huang, H.-J. S., Friedman, T., de Tribolet, N., and Cavenee, W. K. Analysis of the *p53* gene and its expression in human glioblastoma cells. *Cancer Res.*, 54: 649-652, 1994.
- Higuchi, R. Recombinant PCR. In: M. A. Innis, D. H. Gelfand, J. J. Sninsky, and T. J. White (eds.), *PCR Protocols*, pp. 177-183. San Diego, CA: Academic Press, Inc., 1990.
- Hannon, G. J., and Beach, D. p15<sup>INK4B</sup> is a potential effector of TGF- $\beta$ -induced cell cycle arrest. *Nature* (Lond.), 371: 257-261, 1994.
- Ueki, K., Rubio, M. P., Ramesh, V., Correa, K. M., Rutter, J. L., Von Deimling, A., Buckler, A. J., Gusella, J. F., and Louis, D. N. *MTS1/CDKN2* gene mutations are rare in primary human astrocytomas with allelic loss of chromosome 9p. *Hum. Mol. Genet.*, 3: 1841-1845, 1994.
- Sambrook, J., Fritsch, E. F., and Maniatis, T. *Molecular Cloning: A Laboratory Manual*, Ed. 2. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1989.
- Herrin, D. L., and Schmidt, G. W. Rapid, reversible staining of Northern blots prior to hybridization. *Biotechniques*, 6: 196-200, 1988.
- Xiong, Y., Zhang, H., and Beach, D. Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation. *Genes Dev.*, 7: 1572-1583, 1993.
- Kriegler, M. DNA transfer. In: M. Kriegler (ed.), *Gene Transfer and Expression: A Laboratory Manual*, pp. 96-98. New York: Stockton Press, 1990.
- Kamb, A., Liu, Q., Harshman, K., Tavtigian, S., Cordon-Cardo, C., and Skolnick, M. H. Response to "rates of p16 (*MTS1*) mutations in primary tumors with 9p loss." *Science* (Washington DC), 265: 416-417, 1994.
- Reifenberger, G., Reifenberger, J., Ichimura, K., Meltzer, P. S., and Collins, V. P. Amplification of multiple genes from chromosomal region 12q13-14 in human malignant gliomas: preliminary mapping of the amplicons shows preferential involvement of *CDK4*, *SAS*, and *MDM2*. *Cancer Res.*, 54: 4299-4303, 1994.
- He, J., Collins, V. P., Allalunis-Turner, M. J., Godbout R., Day, R. S., III, and James, C. D. *CDK4* amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. *Cancer Res.*, 54: 5804-5807, 1994.

# Cancer Research

The Journal of Cancer Research (1916–1930) | The American Journal of Cancer (1931–1940)

## Replacement of the *p16/CDKN2* Gene Suppresses Human Glioma Cell Growth

Wadih Arap, Ryo Nishikawa, Frank B. Furnari, et al.

*Cancer Res* 1995;55:1351-1354.

**Updated version** Access the most recent version of this article at:  
<http://cancerres.aacrjournals.org/content/55/6/1351>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link <http://cancerres.aacrjournals.org/content/55/6/1351>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.